| Primary |
| Antiplatelet Therapy |
14.6% |
| Hypertension |
14.6% |
| Thrombosis Prophylaxis |
13.1% |
| Anticoagulant Therapy |
7.0% |
| Atrial Fibrillation |
7.0% |
| Acute Myocardial Infarction |
5.6% |
| Coronary Arterial Stent Insertion |
4.7% |
| Coronary Artery Disease |
4.2% |
| Cardiovascular Event Prophylaxis |
3.8% |
| Diabetes Mellitus |
3.8% |
| Prophylaxis |
3.3% |
| Myocardial Ischaemia |
2.8% |
| Analgesic Therapy |
2.3% |
| Angina Pectoris |
1.9% |
| Angina Unstable |
1.9% |
| Antiphospholipid Syndrome |
1.9% |
| Asthma |
1.9% |
| Bronchitis |
1.9% |
| Cardiac Failure |
1.9% |
| Cerebral Infarction |
1.9% |
|
| Angioedema |
49.4% |
| Urticaria |
10.6% |
| Labelled Drug-drug Interaction Medication Error |
5.6% |
| Premature Baby |
3.8% |
| Rash |
3.8% |
| Upper Gastrointestinal Haemorrhage |
3.1% |
| Wheezing |
3.1% |
| Asthenia |
2.5% |
| Cerebral Haemorrhage |
2.5% |
| Anaemia |
1.9% |
| Eye Swelling |
1.9% |
| Haemoglobin Decreased |
1.9% |
| Arrhythmia |
1.3% |
| Dermatitis Exfoliative |
1.3% |
| Gastrointestinal Haemorrhage |
1.3% |
| Haematoma |
1.3% |
| Haemorrhage Intracranial |
1.3% |
| Myocardial Infarction |
1.3% |
| Nausea |
1.3% |
| Premature Delivery |
1.3% |
|
| Secondary |
| Product Used For Unknown Indication |
26.5% |
| Atrial Fibrillation |
18.6% |
| Cerebrovascular Accident Prophylaxis |
12.8% |
| Thrombosis Prophylaxis |
9.1% |
| Drug Hypersensitivity |
3.7% |
| Anticoagulant Therapy |
3.0% |
| Acute Myocardial Infarction |
2.7% |
| Prophylaxis |
2.7% |
| Cerebrovascular Accident |
2.4% |
| Antiplatelet Therapy |
2.1% |
| Hypertension |
2.1% |
| Deep Vein Thrombosis |
1.8% |
| Embolism Venous |
1.8% |
| In Vitro Fertilisation |
1.8% |
| Cardiovascular Event Prophylaxis |
1.5% |
| Hip Arthroplasty |
1.5% |
| Myocardial Ischaemia |
1.5% |
| Pulmonary Embolism |
1.5% |
| Asthma |
1.2% |
| Cardiac Failure |
1.2% |
|
| Product Quality Issue |
13.2% |
| Haemoglobin Decreased |
9.4% |
| Gastrointestinal Haemorrhage |
7.5% |
| Wheezing |
7.5% |
| Haematuria |
5.7% |
| Upper Gastrointestinal Haemorrhage |
5.7% |
| Anaemia |
3.8% |
| Analgesic Asthma Syndrome |
3.8% |
| Haemarthrosis |
3.8% |
| Haemorrhage |
3.8% |
| Mouth Haemorrhage |
3.8% |
| Myalgia |
3.8% |
| Myocardial Infarction |
3.8% |
| Procedural Haemorrhage |
3.8% |
| Rectal Haemorrhage |
3.8% |
| Red Blood Cell Count Decreased |
3.8% |
| Subdural Haematoma |
3.8% |
| Vaginal Haemorrhage |
3.8% |
| Weight Decreased |
3.8% |
| Angioedema |
1.9% |
|
| Concomitant |
| Angina Pectoris |
14.3% |
| Cardiac Failure Chronic |
14.3% |
| Product Used For Unknown Indication |
14.3% |
| Type 2 Diabetes Mellitus |
10.0% |
| Lumbar Spinal Stenosis |
8.6% |
| Atrial Fibrillation |
7.1% |
| Hypertension |
4.3% |
| Arthritis |
2.9% |
| Hepatic Cirrhosis |
2.9% |
| Hepatocellular Carcinoma |
2.9% |
| Hormone Replacement Therapy |
2.9% |
| Plasma Cell Myeloma |
2.9% |
| Pulmonary Embolism |
2.9% |
| Cardiac Disorder |
1.4% |
| Cardiovascular Event Prophylaxis |
1.4% |
| Cerebrovascular Accident Prophylaxis |
1.4% |
| Complex Regional Pain Syndrome |
1.4% |
| Coronary Artery Bypass |
1.4% |
| Diverticulum |
1.4% |
| Dyslipidaemia |
1.4% |
|
| Death |
20.0% |
| No Adverse Event |
10.0% |
| Off Label Use |
10.0% |
| Rash |
10.0% |
| Rash Macular |
10.0% |
| Renal Failure |
10.0% |
| Transferrin Increased |
10.0% |
| Unevaluable Event |
10.0% |
| Ventricular Arrhythmia |
10.0% |
|
| Interacting |
| Product Used For Unknown Indication |
29.7% |
| Atrial Fibrillation |
20.2% |
| Cerebrovascular Accident Prophylaxis |
17.4% |
| Antiplatelet Therapy |
4.2% |
| Blood Pressure Abnormal |
3.5% |
| Hypertension |
3.1% |
| Thrombosis Prophylaxis |
2.9% |
| Blood Cholesterol Abnormal |
2.4% |
| Anticoagulant Therapy |
2.2% |
| Diabetes Mellitus |
2.0% |
| Deep Vein Thrombosis |
1.8% |
| Pain |
1.8% |
| Diuretic Therapy |
1.5% |
| Cardiac Disorder |
1.3% |
| Gastric Disorder |
1.3% |
| Type 2 Diabetes Mellitus |
1.3% |
| Agitation |
0.9% |
| Anxiety |
0.9% |
| Blood Pressure Management |
0.9% |
| Embolism Venous |
0.9% |
|
| Product Quality Issue |
15.2% |
| Haemoglobin Decreased |
10.9% |
| Gastrointestinal Haemorrhage |
8.7% |
| Lower Gastrointestinal Haemorrhage |
6.5% |
| Subdural Haematoma |
6.5% |
| Blood Urine Present |
4.3% |
| Haematochezia |
4.3% |
| Haemorrhage Intracranial |
4.3% |
| Hemiparesis |
4.3% |
| Insomnia |
4.3% |
| Rectal Haemorrhage |
4.3% |
| Upper Gastrointestinal Haemorrhage |
4.3% |
| Vascular Pseudoaneurysm |
4.3% |
| Weight Decreased |
4.3% |
| Cerebellar Haemorrhage |
2.2% |
| Drug Interaction |
2.2% |
| Epistaxis |
2.2% |
| Eye Haemorrhage |
2.2% |
| Fatigue |
2.2% |
| Feeling Abnormal |
2.2% |
|
